CDMO Sterile Fill-Finish 506e Outsourcing Contract Manufacturer for Once-a-Week Insulin Icodec 700u/mL

Insulin icodec is a novel ultra-long-acting basal insulin analog engineered with a fatty acid side chain that enables reversible albumin binding in the bloodstream. This modification creates a large subcutaneous depot following injection, extending the half-life to approximately 196 hours — roughly 8 days. The result is a flat, stable basal insulin profile that provides continuous glycemic coverage across a full week from a single subcutaneous injection. Icodec activates insulin receptors to suppress hepatic glucose production, stimulate peripheral glucose uptake in muscle and adipose tissue, and inhibit lipolysis, closely mimicking physiological basal insulin secretion without daily injection burden.

MayMag Biologics manufactures insulin icodec biosimilars under 506(e) outsourcing facility registration at our GMP-certified facilities in Dallas and Garland, Texas. Our sterile fill-finish services for icodec include aseptic cartridge filling at U-700 concentration, auto-pen assembly in pre-filled 3 mL injector format, cold-chain packaging and temperature-controlled storage, full batch documentation and Certificate of Analysis (CoA), and regulatory submission support. We source icodec API exclusively from FDA-approved and internationally accredited biosimilar manufacturers, ensuring equivalent pharmacokinetic and pharmacodynamic profiles to the reference product at significantly reduced cost — expanding once-weekly insulin access for patients and healthcare systems worldwide.

Insulin degludec is an ultra-long-acting basal insulin analog that self-assembles into soluble multi-hexamer chains upon subcutaneous injection. These multi-hexamers form a stable subcutaneous depot that slowly dissociates into active monomers, which are absorbed into the bloodstream at a consistent, predictable rate. With a half-life exceeding 25 hours and a duration of action up to 42 hours — the longest of any commercially available basal insulin — degludec provides a flat, peakless pharmacokinetic profile with exceptionally low day-to-day variability. This stable profile significantly reduces the risk of nocturnal hypoglycemia while offering flexible once-daily dosing at any time of day. Available in both U-100 and U-200 concentrations, degludec supports individualized dosing for adults, adolescents, and children aged one year and older with Type 1 and Type 2 diabetes.

Our Garland, Texas GMP facility produces insulin degludec biosimilar drug product in pre-filled FlexTouch auto-pen format for both U-100 and U-200 concentrations. MayMag Biologics provides end-to-end sterile fill-finish manufacturing including aseptic filling of 3 mL cartridges at both concentrations, full analytical release testing and ICH-compliant stability programs, auto-pen device assembly and labeled packaging, regulatory documentation and CoA support, and cold-chain logistics. Biosimilar insulin degludec manufactured by MayMag Biologics delivers equivalent pharmacokinetic and pharmacodynamic profiles to Tresiba at substantially reduced cost, supporting broader patient access to ultra-long-acting basal insulin therapy.

Insulin detemir and insulin glargine are established 24-hour basal insulin analogs that provide predictable, peakless glycemic control through distinct molecular mechanisms. Insulin detemir carries a C14 fatty acid chain attached to lysine B29, enabling reversible albumin binding in the bloodstream. This dual mechanism — albumin binding combined with self-association at the injection site — prolongs absorption and extends the duration of action to approximately 24 hours with lower intra-individual variability than NPH insulin. Insulin glargine incorporates two arginine residues at the C-terminus of the B-chain and a glycine substitution at position A21, shifting its isoelectric point to pH 6.7. Upon subcutaneous injection at physiological pH, glargine forms microprecipitates that dissolve slowly, releasing insulin monomers at a consistent, peakless rate over 24 hours. Both analogs activate insulin receptors to suppress hepatic glucose production and promote peripheral glucose uptake, providing reliable once-daily basal coverage for adults and children with Type 1 and Type 2 diabetes.

MayMag Biologics provides contract manufacturing of both insulin detemir and insulin glargine biosimilars at our 506(e)-registered Dallas and Garland, Texas facilities. Our sterile fill-finish services include formulation development and aseptic fill-finish for U-100 cartridges, auto-pen device assembly in FlexPen and SoloStar formats, lyophilization for formulations requiring freeze-drying, ICH-compliant stability testing and full batch release documentation, and regulatory submission support. Biosimilar insulin glargine (including Semglee and Rezvoglar equivalents) and biosimilar insulin detemir are manufactured under contract with FDA-approved API partners, delivering equivalent 24-hour basal glycemic control at reduced cost and strengthening domestic supply chain resilience.

Insulin aspart is a rapid-acting mealtime insulin analog engineered with a single amino acid substitution — proline replaced by aspartic acid at position B28 of the B-chain. This modification reduces self-association of insulin molecules, allowing faster dissociation into monomers and dimers at the subcutaneous injection site compared to regular human insulin. The result is a rapid onset of action within 10–20 minutes of injection, peak effect at 1–3 hours, and a total duration of 3–5 hours. Aspart closely mimics physiological first-phase insulin secretion, providing rapid postprandial glucose control by suppressing hepatic glucose production, stimulating glucose uptake in skeletal muscle and adipose tissue, and inhibiting glucagon secretion. Its shorter duration of action reduces the risk of late postprandial hypoglycemia. Aspart is also compatible with continuous subcutaneous insulin infusion (CSII) pumps, making it suitable for both multiple daily injection and pump-based basal-bolus regimens.

MayMag Biologics offers end-to-end CDMO services for insulin aspart biosimilars through our 506(e)-registered outsourcing facility. Our manufacturing capabilities include aseptic fill-finish for U-100 pre-filled FlexPen cartridges, auto-pen assembly and labeled device packaging, API sourcing through our established Gan & Lee Pharmaceuticals and Biocon Biologics partnerships, full analytical release testing and stability programs, and regulatory documentation and CoA support. Biosimilar insulin aspart manufactured by MayMag Biologics delivers equivalent rapid-acting mealtime glycemic control to NovoLog and NovoRapid at reduced cost, improving access to short-acting insulin therapy for patients managing Type 1 and Type 2 diabetes globally.